Harrow, Inc.

HROW ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $272.3M $199.6M $130.2M $88.6M $72.5M $48.9M $51.2M $41.4M
Cost of Revenue $67.9M $49.2M $39.6M $25.4M $18.2M $14.5M $16.7M $16.5M
Gross Profit $204.4M $150.4M $90.6M $63.2M $54.3M $34.4M $34.4M $24.9M
Gross Margin 75.1% 75.3% 69.6% 71.3% 74.9% 70.4% 67.3% 60.1%
Operating Expenses
Research & Development $20.9M $12.2M $6.7M $3.1M $11.1M $2.4M $2.1M $825.0K
SG&A Expense $152.9M $129.1M $83.1M $58.2M $41.3M $31.2M $33.1M $29.2M
Operating Income $30.5M $8.8M $431.0K $1.9M $1.6M $385.0K $-4.8M $-5.2M
Operating Margin 11.2% 4.4% 0.3% 2.2% 2.2% 0.8% -9.4% -12.6%
Interest Expense $21.3M $7.2M $5.4M
Pretax Income $-1.4M $-17.3M $-23.7M $-14.0M $-17.9M $-3.4M $-117.0K $14.6M
Income Tax Expense $3.8M $161.0K $701.0K $75.0K $133.0K $4.0K $8.0K
Net Income $-5.1M $-17.5M $-24.4M $-14.1M $-18.0M $-3.4M $168.0K $14.6M
Net Margin -1.9% -8.8% -18.7% -15.9% -24.8% -6.9% 0.3% 35.3%
EPS (Basic) $-0.14 $-0.49 $-0.75 $-0.51 $-0.69 $-0.13 $0.01 $0.67
EPS (Diluted) $-0.14 $-0.49 $-0.75 $-0.51 $-0.69 $-0.13 $0.01 $0.61
Shares Outstanding (Basic) 36.8M 35.7M 32.6M 27.5M 26.8M 25.9M 25.3M 21.9M
Shares Outstanding (Diluted) 36.8M 35.7M 32.6M 27.5M 26.8M 25.9M 26.5M 23.8M
Dividends Per Share
← Newer Page 1 of 2 Older →